What Ovctek China does

Ovctek China (欧普康视, Shenzhen ticker 300595) is a Hefei-based medical device company founded in 2000 by Dr. Tao Yuequn (陶悦群), a UC Davis-trained optometrist and recognized returnee expert. The company manufactures and distributes orthokeratology (OK) lenses under its flagship Mengdaiwei (梦戴维) and DreamVision brands, with DK185 as the proprietary ultra-high oxygen permeable material that underpins the product line. Ovctek was the first domestic Chinese manufacturer to receive NMPA Class III medical device approval for OK lenses, and has built a portfolio spanning RGP lenses (Ridaiwei 日戴维, Huazhui 华锥), soft contact lenses, scleral lenses (DreamVisionSL), defocus lenses, lens care products (Jingteshu 镜特舒), visual function training devices, and dry eye treatments.

The company operates a vertically integrated model combining proprietary materials R&D, automated production at a 45,000+ sqm facility, and a multi-channel distribution network covering 1,500+ medical institutions, 500+ dedicated retail terminals (欧普眼视光), 400+ retail chain locations, 10+ subsidiary Kangshi Eye Hospitals, and 30+ provinces. Pricing per OK lens pair ranges from 3,000 to 10,000+ RMB, with 2M+ cumulative users served. The 2025 strategic cooperation with PICC Health Insurance extends the customer base into insured populations, while the 2023 acquisition of Fengxian Huaming Eye Hospital and the 2023 full domestic production of lens care products reflect deeper vertical integration. The company pursues revenue through a mix of B2B sales to hospitals and clinics, B2C retail at owned terminals, and increasingly through owned hospital services.

Name

Ovctek China

Legal name

欧普康视科技股份有限公司

Website

https://orthok.cn

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Ovctek China (欧普康视) is a Hefei-based, Shenzhen-listed (300595) manufacturer of orthokeratology lenses and related ophthalmic products, serving 1,500+ medical institutions, 500+ retail terminals, and 10+ subsidiary eye hospitals across China with its proprietary DK185 material.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices (Orthokeratology & Rigid Contact Lenses)

NAICS

Ophthalmic Goods Manufacturing (339115), Optical Goods Retailers (45613), Offices of Optometrists (62132)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)

akta.pro secondary industries

Contact Lens Specialty & Myopia Control (HLAKAKAK), Optical Dispensing & Eyewear Retail (Glasses/Frames/Lenses) (HLAKAKAL), Optometry Clinics (Primary Eye Care) (HLAKAKAB)

Keywords

• Orthokeratology lenses
• Rigid gas permeable contact lenses
• Myopia control products
• Ophthalmic medical devices
• Rigid lens care solutions

Headquarters

HQ city

Hefei

HQ country

China

HQ region

Asia

Offices14 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Orthokeratology Lens Products: Sale of rigid gas permeable contact lenses including orthokeratology lenses (梦戴维, DreamVision, AP185, DV185 series), RGP lenses (日戴维), and scleral lenses. Products are customized per individual corneal parameters with pricing ranging from 3000-10000+ RMB per pair depending on product tier and customization level.
2. Eye Health Care Products: Lens care solutions including cleaning solutions, rinsing solutions, lubricating drops, and deep cleaning products under the '镜特舒' brand. Recently achieved full domestic production capability, replacing previously imported products.
3. Eye Health Services (欧普眼视光): Retail eye health services through 400+ chain stores providing eye examinations, myopia prevention and control services, dry eye treatment, optometry, and glasses dispensing. Revenue from service fees at owned and franchised retail locations.
4. Training and Certification Services: Vocational skills training for optometry technicians (眼镜验光员, 眼镜定配工) through the company's training school. Certification examination fees and training course fees. Also offers '儿童青少年近视防控' certification courses.
5. Hospital and Medical Services: Revenue from subsidiary eye hospitals (康视眼科医院) including Anhui Medical University Kangshi Eye Hospital, providing medical services, surgeries, and comprehensive eye care.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

Ovctek China manufactures and sells rigid gas permeable contact lenses, primarily orthokeratology (OK) lenses for overnight myopia correction, including the DreamVision, AP185, DV185, and 梦戴维 (Mengdaiwei) product lines, plus the DreamVisionSL scleral lens and a complete line of lens care solutions under the 镜特舒 (Jingteshu) brand. The company also operates a vertically integrated eye health ecosystem including 500+ retail eye care service centers (欧普眼视光), 10+ subsidiary eye hospitals, vocational training school for optometry technicians, and certifies optometrists across China. Products are Class III medical devices distributed to 1,500+ medical institutions and through direct-to-consumer channels.

Product overview

Ovctek China (欧普康视科技股份有限公司, OVCTEK) is a medical device company specializing in ophthalmic and optometric products, offering a comprehensive eye health portfolio spanning rigid contact lenses, lens care solutions, and eye health products. The core product line consists of orthokeratology (OK) lenses — including 梦戴维 (Mengdaiwei), DV185, AP185, and DreamVisionGP — used for overnight myopia correction; the DreamVisionSL scleral lens for daytime correction of myopia/hyperopia; the 日戴维 (Riwaiwei) soft hydrophilic contact lens for daily myopia correction; and the 镜特舒 (Jingteshu) complete rigid lens care product line (cleaning, rinsing, lubricating, deep cleaning solutions). The company also offers visual function training products, dry eye/presbyopia treatment products, and eye health supplements. All products are sold through a network of medical institutions and the company's own eye care service brand 欧普眼视光.

Differentiator

Problem solved

Functional benefit

Brands

• 梦戴维: 角膜塑形镜品牌，适用于青少年近视矫正
• DreamVision
• 日戴维
• 镜特舒
• DVSL
• 华锥

Products and services

• DreamVisionSL Scleral Lens (DreamVisionSL 巩膜镜) A large-diameter rigid gas permeable scleral contact lens (12.5–16.5mm) for daytime wear, using DK185 ultra-high oxygen permeability material, landing on the sclera without touching the cornea, with a 1.43 high refractive index and UV absorption Class 2. Indicated for correction of myopia and hyperopia in adults.
• 梦戴维 Corneal Orthokeratology Lens (梦戴维 角膜塑形镜) Orthokeratology lens for overnight wear, providing clear daytime vision without glasses. Available for myopia up to -6.00D and astigmatism ≤1.50D. Suitable for adolescents and young adults.
• DV185 Corneal Orthokeratology Lens (DV185 角膜塑形镜) Ultra-high oxygen permeability corneal orthokeratology lens using DK185 material with intelligent surface shape optimization and dynamic e-value design, produced via fully automated manufacturing. For myopia in range -0.50D to -4.00D and astigmatism ≤1.50D.
• AP185 Corneal Orthokeratology Lens (AP185 角膜塑形镜) Ultra-high oxygen permeability corneal orthokeratology lens using DK185 material with full aspherical design for personalized fitting, optimized tear circulation, and comfortable lens-to-corneal parallel adaptation. For myopia in range -0.50D to -4.00D and astigmatism ≤1.50D.
• 日戴维 Soft Hydrophilic Contact Lens (日戴维 软性亲水接触镜) Soft hydrophilic contact lens with progressive multifocal design for daily wear, indicated for myopia correction. Available in diopter range -1.00D to -10.00D, with 55% water content, bi-weekly replacement cycle.
• DreamVisionGP Orthokeratology Lens (DreamVisionGP 角膜塑形镜) Premium corneal orthokeratology lens line with automated precision manufacturing, offering high-definition stable vision correction.
• 华锋 (Huazhui) RGP Rigid Gas Permeable Contact Lens Rigid gas permeable contact lens for daily wear, suitable for high myopia, high astigmatism, and keratoconus patients, providing high optical imaging quality.
• 镜特舒 Rigid Lens Care Product Series (镜特舒 硬镜护理系列) Complete line of rigid contact lens care products including cleaning solution (国械注准20193160702), rinsing solution (国械注准20223160340), wetting/lubricating drops (国械注准20233160127), and weekly deep cleaning solution.
• 梦戴维精适减离焦镜片 (Mengdaiwei Defocus Lens) Defocus lens with small optical zone design for myopia management, worn during the day for progressive defocus effect to slow myopia progression.
• 欧普康视眼视光技术培训学校 - Optometry Technician Training & Certification Service Vocational skills training service for optometry technicians (眼镜验光员, 眼镜定配工) through the company's training school, with certification examination fees and training course fees. Includes 'Children & Adolescents Myopia Prevention & Control' certification courses.
• 欧普眼视光 (Ovctek Vision) Eye Health Service Chain Retail eye health services through 400+ chain stores providing eye examinations, myopia prevention and control services, dry eye treatment, optometry, and glasses dispensing. Revenue from service fees at owned and franchised retail locations.
• Kangshi Eye Hospital Chain (康视眼科医院连锁) Eye hospital medical services including treatments, surgeries, and comprehensive eye care through subsidiary eye hospitals (Anhui Medical University Kangshi, Bengbu Kangshi, Ma'anshan Kangshi, Lu'an Kangshi, Xuancheng Kangshi, Guangde Kangshi, Langxi Huayi, Ningguo Vision, Qingdao Zejia, Shangrao Qiming, Xi'an Yanliang Kangshi).

Quantifiable outcome

• Cumulative 2 million+ orthokeratology lens users since inception
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core, major and minor.

• 中国人保健康 (PICC Health Insurance)coreGTM or Marketing Partner · 31 March 2025Strategic cooperation for national comprehensive eye care service project. Won bid to become core service provider. Provides eye health services to insurance customers nationwide including eye exams, myopia prevention, optometry, dry eye treatment.
• 温州医科大学 (Wenzhou Medical University)coreStrategic or Co-development Partner · 12 February 2025Official '就业实践基地' (Employment Practice Base) granted. Deepened cooperation in industry-education integration and talent development.
• 温州医科大学 (Wenzhou Medical University)coreStrategic or Co-development Partner · 10 November 2024Strategic cooperation including employment practice base establishment. University president visit in November 2024. Cooperation in talent cultivation, clinical trials, and R&D achievement translation.
• 安徽省眼科医院 (Anhui Provincial Eye Hospital)majorStrategic or Co-development Partner · 25 June 2023Medical alliance partnership. 9 Kangshi Eye hospitals joined as members. Provides technical guidance and professional support through community-based 欧普眼视光 network.
• 安徽医科大学 (Anhui Medical University)coreStrategic or Co-development Partner · 21 August 2020Comprehensive strategic cooperation including 10 million RMB donation for '欧普康视眼视光学院' construction. Joint establishment of Anhui Medical University Kangshi Eye Hospital. Cooperation covers talent cultivation, clinical research, and industry-academia-research integration.
• 皖西卫生职业学院majorStrategic or Co-development PartnerSchool-enterprise cooperation: '实习就业基地' at company, '人才培养基地' at school, '教学医院' at Lu'an Kangshi Eye Hospital. Focus on optometry technician training.
• 安徽卫生健康职业学院majorStrategic or Co-development PartnerSchool-enterprise cooperation: '实习就业基地' at company, '人才培养基地' at school. Cultivating optometry professionals for the industry.
• 白城医学高等专科学校majorStrategic or Co-development PartnerJoint establishment of '欧普眼视光创新学院'. Modern apprenticeship training model. Cooperation in corneal contact lenses, visual training, and optometry medical devices.
• 丰县华明眼科医院minorStrategic or Co-development PartnerSubsidiary investment: 22.44 million RMB for 51% stake in Fengxian Huaming Eye Hospital. First controlled eye hospital in Jiangsu region. Regional network expansion.
• 中国华侨公益基金会majorStrategic or Co-development PartnerExecuting '侨爱心·光明行' charity program in Hefei. Anhui Medical University Kangshi Eye Hospital provides free medical treatment for impoverished cataract patients.
• 安徽省第八批援藏工作队majorStrategic or Co-development PartnerAnnual '加强近视防控 关爱高原学子' Tibet myopia prevention aid program. 4 consecutive years of collaboration (2022-2025). Free vision screening and glasses donation for Tibet students.
• 安徽省药品监督管理局majorOthersGuiding and supporting organization for medical device innovation. Sponsorship of '欧普康视科创杯' Anhui Medical Device Innovation Competition for three consecutive years.
• 13+ Vocational SchoolsmajorStrategic or Co-development PartnerSchool-enterprise cooperation network including Anhui Medical Higher Specialized School, Jinling Institute of Technology, and others. Industry-academia-research integration for optometry talent cultivation.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Alcon: Global eye care leader with contact lens, lens care (OPTI-FREE, AOSept), and surgical ophthalmic product lines. Broad incumbent in optical goods and lens care markets relevant to Ovctek's portfolio.
• CooperVision: Major global contact lens manufacturer with broad soft and specialty lens lines including MiSight myopia management lens. Overlaps with Ovctek in contact lens category but with global portfolio rather than OK specialization.
• Johnson & Johnson Vision: Global contact lens leader (Acuvue brand) with growing myopia management portfolio. Competes broadly in contact lenses and lens care; a significant potential entrant in Asia myopia management given its R&D scale.
• Bausch + Lomb (Bausch Health): Global ophthalmic goods manufacturer with broad contact lens, lens care, and ophthalmic surgical portfolios. Competes with Ovctek in RGP lens care solutions and broad optical goods, but does not specialize in China's OK lens segment.

Direct peers

• Paragon Vision Sciences: Manufacturer of corneal reshaping / orthokeratology contact lenses including CRT® (Corneal Refractive Therapy). Direct peer in specialty RGP and OK lens category with comparable Class III regulatory footprint and clinical channel.
• Menicon: Japan-based specialty contact lens manufacturer with significant orthokeratology and RGP lens portfolio. Direct peer in OK lens product category with comparable technology positioning and regulatory pathway in Asia-Pacific markets.
• Euclid Systems Corporation: US-based orthokeratology lens manufacturer (Emerald™ and other OK lens lines). Direct competitor in the same overnight OK lens product category serving myopia control, with similar clinical positioning and Class III regulatory pathway in respective geographies.

Regional players

• St. Shine Optical: Taiwan-listed contact lens manufacturer producing both soft and specialty lenses including OK lens products. Regional peer in Greater China market with comparable product category but Taiwan-based operations rather than mainland focus.
• Brighten Optix (亨泰光学): Taiwan-based specialty contact lens company with orthokeratology (Briox) and corneal reshaping products. Regional peer competing in Greater China OK lens market with similar clinical product positioning.

Emerging players

• Xingqi Eye Care Pharmaceutical (兴齐眼药): Shenzhen-listed Chinese ophthalmic pharmaceutical and device company developing orthokeratology lenses and myopia care products. Domestic peer with overlapping myopia control focus but broader ophthalmic pharmaceutical base.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ovctek China